Moreover, our work and others have shown that combinations with epigenetic modifying agents including HDACi [75] and bromodomain inhibitors [237] may enhance p53 induced cell death through more than one of these mechanisms and intriguingly, bispecific small molecules targeting MDM2 with BRD4, BCL2, and XIAP present interesting strategies for wild-type p53 containing tumours [238,239,240]. The gene discussed is MDM2; the disease is neoplasm.